Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer

Abstract PD-L1 expression is the most useful predictive biomarker for immunotherapy efficacy on non-small cell lung cancer (NSCLC), and CD8+ tumor-infiltrating lymphocytes (CD8+ TILs) play an essential role in the clinical activity of immunotherapy. PD-L1 is found on the exosome’s surface, and PD-L1...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yoshihisa Shimada, Jun Matsubayashi, Yujin Kudo, Sachio Maehara, Susumu Takeuchi, Masaru Hagiwara, Masatoshi Kakihana, Tatsuo Ohira, Toshitaka Nagao, Norihiko Ikeda
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/d31a0af264a74150afd7934cd02db857
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d31a0af264a74150afd7934cd02db857
record_format	dspace
spelling	oai:doaj.org-article:d31a0af264a74150afd7934cd02db8572021-12-02T18:15:45ZSerum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer10.1038/s41598-021-87575-32045-2322https://doaj.org/article/d31a0af264a74150afd7934cd02db8572021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-87575-3https://doaj.org/toc/2045-2322Abstract PD-L1 expression is the most useful predictive biomarker for immunotherapy efficacy on non-small cell lung cancer (NSCLC), and CD8+ tumor-infiltrating lymphocytes (CD8+ TILs) play an essential role in the clinical activity of immunotherapy. PD-L1 is found on the exosome’s surface, and PD-L1 expressing exosomes can inhibit antitumor immune responses. This study aimed to analyze tumor PD-L1 expression, serum exosomal PD-L1, and CD8+ TILs to investigate anti-PD-1 response and clinicopathological outcomes in NSCLC. One hundred twenty patients with stage I–III NSCLC were enrolled, and serum samples collected during the initial surgery were pooled. The Human CD274/PD-L1 ELISA kit was used to quantify the exosomal PD-L1. Exosomal PD-L1 levels were significantly correlated with tumor PD-L1 levels (p < 0.001) and the number of CD8+ TILs (p = 0.001). Patients with exosomal PD-L1 ≥ 166 pg/mL tended to have a worse RFS than those with < 166 pg/mL in all stage (p = 0.163) and stage I patients (p = 0.116). Seventeen patients exhibited postoperative recurrences and received anti-PD-1 treatment. The disease control rate of patients with exosomal PD-L1 ≥ 166 pg/mL was 100%. The measurement of serum exosomal PD-L1 as a quantitative factor with tumor PD-L1 status may help predict anti-PD-1 response and clinical outcomes in patients with NSCLC.Yoshihisa ShimadaJun MatsubayashiYujin KudoSachio MaeharaSusumu TakeuchiMasaru HagiwaraMasatoshi KakihanaTatsuo OhiraToshitaka NagaoNorihiko IkedaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yoshihisa Shimada Jun Matsubayashi Yujin Kudo Sachio Maehara Susumu Takeuchi Masaru Hagiwara Masatoshi Kakihana Tatsuo Ohira Toshitaka Nagao Norihiko Ikeda Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer
description	Abstract PD-L1 expression is the most useful predictive biomarker for immunotherapy efficacy on non-small cell lung cancer (NSCLC), and CD8+ tumor-infiltrating lymphocytes (CD8+ TILs) play an essential role in the clinical activity of immunotherapy. PD-L1 is found on the exosome’s surface, and PD-L1 expressing exosomes can inhibit antitumor immune responses. This study aimed to analyze tumor PD-L1 expression, serum exosomal PD-L1, and CD8+ TILs to investigate anti-PD-1 response and clinicopathological outcomes in NSCLC. One hundred twenty patients with stage I–III NSCLC were enrolled, and serum samples collected during the initial surgery were pooled. The Human CD274/PD-L1 ELISA kit was used to quantify the exosomal PD-L1. Exosomal PD-L1 levels were significantly correlated with tumor PD-L1 levels (p < 0.001) and the number of CD8+ TILs (p = 0.001). Patients with exosomal PD-L1 ≥ 166 pg/mL tended to have a worse RFS than those with < 166 pg/mL in all stage (p = 0.163) and stage I patients (p = 0.116). Seventeen patients exhibited postoperative recurrences and received anti-PD-1 treatment. The disease control rate of patients with exosomal PD-L1 ≥ 166 pg/mL was 100%. The measurement of serum exosomal PD-L1 as a quantitative factor with tumor PD-L1 status may help predict anti-PD-1 response and clinical outcomes in patients with NSCLC.
format	article
author	Yoshihisa Shimada Jun Matsubayashi Yujin Kudo Sachio Maehara Susumu Takeuchi Masaru Hagiwara Masatoshi Kakihana Tatsuo Ohira Toshitaka Nagao Norihiko Ikeda
author_facet	Yoshihisa Shimada Jun Matsubayashi Yujin Kudo Sachio Maehara Susumu Takeuchi Masaru Hagiwara Masatoshi Kakihana Tatsuo Ohira Toshitaka Nagao Norihiko Ikeda
author_sort	Yoshihisa Shimada
title	Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer
title_short	Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer
title_full	Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer
title_fullStr	Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer
title_full_unstemmed	Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer
title_sort	serum-derived exosomal pd-l1 expression to predict anti-pd-1 response and in patients with non-small cell lung cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/d31a0af264a74150afd7934cd02db857
work_keys_str_mv	AT yoshihisashimada serumderivedexosomalpdl1expressiontopredictantipd1responseandinpatientswithnonsmallcelllungcancer AT junmatsubayashi serumderivedexosomalpdl1expressiontopredictantipd1responseandinpatientswithnonsmallcelllungcancer AT yujinkudo serumderivedexosomalpdl1expressiontopredictantipd1responseandinpatientswithnonsmallcelllungcancer AT sachiomaehara serumderivedexosomalpdl1expressiontopredictantipd1responseandinpatientswithnonsmallcelllungcancer AT susumutakeuchi serumderivedexosomalpdl1expressiontopredictantipd1responseandinpatientswithnonsmallcelllungcancer AT masaruhagiwara serumderivedexosomalpdl1expressiontopredictantipd1responseandinpatientswithnonsmallcelllungcancer AT masatoshikakihana serumderivedexosomalpdl1expressiontopredictantipd1responseandinpatientswithnonsmallcelllungcancer AT tatsuoohira serumderivedexosomalpdl1expressiontopredictantipd1responseandinpatientswithnonsmallcelllungcancer AT toshitakanagao serumderivedexosomalpdl1expressiontopredictantipd1responseandinpatientswithnonsmallcelllungcancer AT norihikoikeda serumderivedexosomalpdl1expressiontopredictantipd1responseandinpatientswithnonsmallcelllungcancer
_version_	1718378362255179776

Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer

Ejemplares similares